Skip to content

Vera Therapeutics VERA Accounts Payable

Accounts Payable at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$489.3M+10.0%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$12.91M-16.0%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$2.66M-36.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$10.03M-43.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$13.31M+243%
Immunome logo
ImmunomeIMNM
$5.53M-39.4%

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's accounts payable?
Vera Therapeutics (VERA) reported accounts payable of $13.91M in Q1 2026.
How has Vera Therapeutics's accounts payable changed year-over-year?
Vera Therapeutics's accounts payable increased by 50.2% year-over-year, from $9.26M to $13.91M.
What is the long-term trend for Vera Therapeutics's accounts payable?
Over 4 years (2021 to 2025), Vera Therapeutics's accounts payable has grown at a 83.3% compound annual growth rate (CAGR), from $5.51M to $62.27M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.